, /PRNewswire/ -- Vivex Biomedical, Inc. and Arthrex Inc. have signed a new long-term agreement that strengthens the partnership between a leading provider of proprietary biologics and a premier innovator of orthopedic surgical solutions.
The multi-year commitment reinforces the vision shared by Vivex Biomedical and Arthrex to progress clinical, surgical and therapeutic patient care.
"This long term agreement grows our relationship with Arthrex to a whole new level by significantly expanding the breadth of Vivex Biomedical products to be made available through Arthrex," said , CEO of Vivex Biomedical. "More importantly, the growing relationship between Arthrex and Vivex Biomedical reinforces our shared vision of enhancing the quality of patient care."
This expanded relationship complements years of successfully pioneering the development and distribution of BioCartilage by Arthrex and Vivex Biomedical, through its Tissue Bank. BioCartilage serves as a scaffold over a microfractured defect, and provides a tissue network that can potentially signal autologous cellular interactions and improve the degree and quality of tissue healing within a properly prepared articular cartilage defect.
"As with BioCartilage, the continued partnership between Arthrex and Vivex Biomedical will support the further development and distribution of quality Orthobiologic technologies," said , Director of Orthobiologics at Arthrex. "Expanding our relationships with partners like Vivex Biomedical helps further our mission of helping surgeons treat their patients better."
About Vivex Biomedical, Inc.
Vivex Biomedical, Inc., (www.vivex.com) is a privately held company based out of focused on cellular therapies that treat orthopaedic, spine, wound and soft tissue indications. Vivex Biomedical and its wholly owned subsidiary, UMTB Biomedical, Inc., own and hold exclusive rights to proprietary technologies in the field of biomedicine, stem cells, and orthopaedic implant surface modification. The Vivex Biomedical technology includes marrow isolated adult multilineage inducible () cell identification and processing, as well as, mimetic patterning technologies (MIME) which can improve the efficiency and efficacy of a patient's healing cascade and reduce the overall cost of healthcare.
Published at PR NewsWire